[The patients' cost of the montelukast therapy due to the generic substitution].

CONCLUSION: Due to the generic competition, the patients' access to drugs containing montelukast sodium increased significantly: the DOT increased, the co-payment decreased. Orv Hetil. 2018; 159(17): 682-687. PMID: 29681174 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29681174?dopt=Abstract

Source: Orvosi Hetilap - April 1, 2018 Category: General Medicine Authors: Répásy B, Endrei D, Zemplényi A, Ágoston I, Boncz I Tags: Orv Hetil Source Type: research